Immune Checkpoint Inhibitors in HCC: Where Do They Fit in the Treatment Algorithm?

Access Course

 

Immune Checkpoint Inhibitors in HCC: Where Do They Fit in the Treatment Algorithm? Experts discuss the current role of checkpoint inhibition in hepatocellular cancer (HCC) as well as the emergence of combination therapies.

 

The goal of this activity is to increase understanding of the latest advances in the use of immunotherapy for the treatment of HCC.

 

This activity is intended for hematologists/oncologists, gastroenterologists, nurses/nurse practitioners, pharmacists, and other healthcare professionals who treat patients with advanced hepatocellular cancer.

 

Learning Objectives:

  • Have increased knowledge regarding the clinical trial data on the use of immune checkpoint inhibitors (ICIs) in managing unresectable HCC.
  • Have greater competence related to identifying when an ICI should be considered for a patient with unresectable/advanced HCC.
  • Have greater competence related to managing immune-related adverse events (irAEs) in patients with unresectable HCC.

 

Approximate Time to Complete: 45 minutes

 

Credit Available: May 8, 2020 - May 8, 2021

 

Developed through a partnership between SITC and Medscape.

sitc_log_color.png     

Medscape_EDU-RGB-2x-300.png

 

Additional Resources for Clinicans from SITC:

 

sitc-cig-rgb.png

 

 

 

 

View Guidelines Here.

 

Accreditation Council for Continuing Medical Education and ABIM Maintenance of Certification
AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit: 0.75
Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s)™: 0.75
American Nurses Credentialing Center's Commission on Accreditation
Contact Hour: 0.75
Accreditation Council for Pharmacy Education
CEU: 0.75